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ABSTRACT 
Background: Protection after meningococcal C (MenC) conjugate (MCC) 
vaccination in early childhood is short-lived. Boosting with a quadrivalent vaccine in 
teenage years, a high risk period for MenC disease, should protect against additional 
serogroups but might compromise MenC response. The carrier protein in the primary 
MCC vaccine determines the response to MCC booster in toddlers, but the 
relationship between primary vaccine and booster given later is unclear. This study 
compared responses to a CRM or TT-conjugated MenACWY vaccine in teenagers 
primed with different MCC vaccines at pre-school age. 
Methods: 93 teenagers (16-19 years), who were previously randomised at age 3-6 
years to receive single-dose MCC-CRM or MCC-TT, were randomised to receive 
either MenACWY-CRM or MenACWY-TT booster. Serum bactericidal antibodies 
(SBA, protective titer ≥8) were measured before, 1 month, and 6 or 9 months after 
boosting. 
Results: Pre-boosting, MCC-TT-primed teenagers had significantly higher MenC 
SBA titers than those MCC-CRM-primed (p=0.02). Post-boosting, both MenACWY 
vaccines induced protective SBA titers to all four serogroups in most participants 
(≥98% at 1 month and ≥90% by 9 months post-boost). The highest MenC SBA titers 
were seen in those MCC-TT-primed and MenACWY-TT boosted (GMT~22,000) 
followed by those boosted with  MenACWY-CRM irrespective of  priming 
(GMT~12,000) and then those MCC-CRM-primed and MenACWY-TT boosted 
(GMT~5,500). The estimated post-booster MenC SBA decline beyond 1 month was 
~40% as time since booster doubles. Both vaccines were well tolerated with no 
attributable serious adverse events. 
Abstract
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Conclusion: Both MenACWY vaccines safely induced protective sustained antibody 
responses against all targeted serogroups in MCC-primed teenagers. 
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INTRODUCTION 
As meningococcal serogroup C (MenC) disease occurs primarily in infants and 
teenagers, the introduction of MenC conjugate (MCC) vaccination into the U.K. 
immunisation schedule in 1999 was complemented by a catch-up vaccination 
campaign to 18 years of age (1). This led to rapid and marked reductions in disease 
incidence (1), attributable deaths (2), and carriage (3, 4), with evidence of herd 
protection (5). However, poor antibody persistence was observed in infants and 
young children (6, 7), raising concerns about sustained protection since persistent 
serum bactericidal antibody (SBA) determines long-term efficacy (8). To extend 
antibody persistence, in 2006 the immunisation schedule was restructured to two 
priming MCC doses in infancy, using vaccines conjugated to either tetanus toxoid 
(TT) (NeisVac-C®) or a diphtheria toxin variant, CRM197 (CRM) (Menjugate® or 
Meningitec®); and a booster at 12 months of age using Menitorix® (MCC-TT plus 
Haemophilus influenza type b (Hib)). Despite this, antibody persistence remained 
poor (9). 
 
To ensure protective antibody through the teenage years, which is a high-risk period 
for disease and carriage (4), a teenage MCC booster dose was introduced from 
2013 (10) to directly protect vaccinees and help ensure maintenance of herd 
protection in the UK. However, it remains unclear how the different vaccines used in 
the childhood immunisation schedule would affect booster responses in teenagers. 
Response to MCC booster given at 12 months of age depends on the primary 
vaccine given, with post-booster MenC SBA titers higher in children primed with 
MCC-TT than those primed with MCC-CRM (9). In children primed with MCC-TT, 
Hib-MCC-TT, or MCC-CRM, and then given MCC-TT at age 13-14 months, the 
Manuscript
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MenC-protected proportion (SBA titers ≥8) at 5 years post booster was highest in 
those primed with MCC-TT (11). Better understanding of these interactions between 
priming and booster vaccines and carrier proteins would help further inform 
meningococcal vaccination policy, but this has not previously been studied in 
teenagers.  
 
To investigate this, we identified a cohort of teenagers who were randomised to 
receive either MCC-TT (NeisVac-C®) or MCC-CRM (Meningitec® or Menjugate®) at 
age 3.5-6 years during a trial conducted before the national introduction of MCC in 
1999 (12), and were thus ideally suited to assess the response to a CRM or TT-
conjugated booster given in the teenage years. Moreover, an alternative to boosting 
with MCC vaccines would be to use quadrivalent conjugate vaccines offering 
additional benefit in protection from serogroups A, Y and W. In view of recent 
evidence of increased W disease (13) a policy of boosting with a MenACWY vaccine 
was considered, but there were concerns about possible interference with the C-
specific response (14). Therefore this trial assessed and compared the 
immunogenicity and safety of either a CRM-conjugated (MENVEO®, Novartis, 
Siena, Italy) or TT-conjugated (NIMENRIX®, GlaxoSmithKline, Rixensart, Belgium) 
MenACWY vaccine in teenagers who received either MCC-TT or MCC-CRM during 
a primary vaccination study 12-14 years earlier. The main aim was to evaluate the 
role of MCC primary vaccine carrier proteins on responses to MenACWY vaccine in 
teenagers.  
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METHODS 
Participants were recruited from a cohort of teenagers in Hertfordshire and 
Gloucestershire, England, who were randomised to receive a single dose of MCC 
between 3.5 and 5.9 years of age, during a previous study between January 1998 
and May 2000 (12) (Figure 1). Healthy volunteers from that cohort who were still 
locally available, eligible, and provided written consent, were grouped by primary 
vaccine and randomised to receive either CRM-conjugated or TT-conjugated 
MenACWY booster. Sera were collected before; 28 days after, and either 6 or 9 
months after booster to allow modelling of antibody decline by time since booster. 
Seroprotected proportions (SBA titers ≥8), ≥4-fold rises in SBA titer, SBA geometric 
mean titers (GMTs), and IgG geometric mean concentrations (GMCs) were 
calculated. Pre-boost antibody levels were compared by primary vaccine using a 
Kruskal-Wallis test, while normal errors regression modelling was used to analyse 
post-vaccination measurements (see further details in Supplemental Digital Content 
1 (SDC-1)). Antibody data were modelled as log-titer against log-time to assess 
decline over time using a fixed effects model to allow for decline in individual 
responses, as previously described (9). The aim of the trial was to estimate the 
percentages of subjects achieving protective antibody levels in each treatment group 
with 95% CI widths ≤ ±10% (assumed observed percentage ≥90%), needing a 
sample size of 50 in each study group. However it was acknowledged from the 
outset that recruitment was unpredictable due to the strictly restricted pool of 
potential participants drawn from a specific previous study cohort. The eventual 
numbers recruited were lower than aimed, with corresponding effects on estimates 
precision and detectable differences. The subset of children who participated in the 
current study were similar to those who did not, with respect to age at preschool 
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vaccination and the proportions that received each of the three primary MCC 
vaccines, while gender proportions differed (38.7% male among current study 
participants, compared to 52.1% among non-participants, p=0.02). The primary 
response to MCC vaccine in the original study was similar between the current study 
participant subset and non-participants (Table S1 in SDC-2). 
 
MenACWY conjugate vaccines were provided by the manufacturers. Novartis MenACWY 
contains capsular oligosaccharides conjugated to CRM197 (15), while GSK MenACWY is 
conjugated to TT (16-18). Primary vaccines used in the original study were previously 
described (12). Reactions were monitored via telephone, self-completed diary, and enquiry 
at study visits. The trial was authorised by the UK Medicines and Healthcare products 
Regulatory Authority and conducted in accordance with the Helsinki Declaration (2008). It 
was registered with the clinical trials registration site www.ClinicalTrials.gov (identifier 
NCT01192997).  
 
 
RESULTS 
A total of 93 teenagers were enrolled (Figure 1), aged 16-19 years, with a period of 
12-14 years between primary (preschool) and booster (teenage) vaccination. Pre-
boost, 1-month post-boost, and persistence blood samples were provided by 93, 92 
and 91 participants, respectively. 
 
Pre-boost serology: Teenagers who were randomised for primary vaccination with 
MCC-TT had significantly higher MenC SBA GMT than those primed with either of 
the MCC-CRM primary vaccines (p=0.02). Also, a relatively greater proportion of 
them still had protective SBA titer, although confidence intervals overlapped with the 
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MCC-CRM-primed groups (Table 1). Individual-level data from the original preschool 
study was accessed to compare historical post-primary titers (after MCC vaccination 
≥12 years previously) with corresponding pre-MenACWY booster titers obtained in 
the current study. Whilst most individual SBA titers had waned since priming, post-
primary and pre-boost SBA titers (Figure 2) were positively associated (rank 
correlation r = 0.45 with all data or 0.57 excluding two participants with post-primary 
titer <8). Notably, 73% (11/15) of the highest initial responders (SBA titer ≥8192) still 
had titers ≥8 over a decade later, compared with 25% (6/24) of those with more 
moderate post-primary titers (64-4096). 
 
Participants had raised tetanus and diphtheria antibody levels, which was as 
anticipated since vaccines against both are included in UK routine immunisation 
schedules. 
 
Post-boost MenC serology: One month post-booster, 100% of participants 
achieved protective serogroup-specific SBA responses against all four 
meningococcal serogroups, except for 2% for MenY in those boosted with 
MenACWY-CRM (Table 2). When categorised by primary vaccine (Table 1) there 
was also 100% seroprotection in all categories, except for 3% for MenY in those 
primed with MCC-TT. Therefore a limited number of MCC-TT-primed individuals who 
received CRM-conjugated booster did not achieve MenY seroprotection. Protected 
proportions were similar whether gauged by the ≥8 titer threshold or conservatively 
by ≥128 (not shown). SBA titers showed evidence of an interaction between the 
primary vaccine and the booster given (p=0.03). This appeared to arise from 
MenACWY-TT generating significantly (p<0.001) higher SBA titers in those primed 
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with MCC-TT (GMT ~ 6400, 4800, 21600 for Menjugate, Meningitec and NeisVac-C, 
respectively); whereas MenACWY-CRM-boosted individuals showed no difference 
(p=0.81) by primary vaccine (GMT ~ 11100, 13000, 11100 for Menjugate, Meningitec 
and NeisVac-C, respectively) (Figure 3; and see Table S2 in SDC-3). Comparisons 
across the six study arms, based on non-overlapping 95% CIs, showed no further 
remarkable post-booster variations (Figure 3). To compare the 1-month teenage 
post-booster responses observed in this study with the responses to primary 
childhood vaccination measured in the original study, logged (teenage) post-boost 
titers were modelled on logged (original) post-primary titers, taking account of the 
primary and booster vaccines received. Associations between post-primary and 
post-boost MenC antibody for both SBA and IgG levels were weak and not 
statistically significant (r=0.27, p=0.26 for SBA; r=0.21, p=0.09 for IgG ELISA). In 
contrast to IgG, SBA responses showed comparatively less variability and generally 
higher post-boost relative to post-primary titers (see Figure S1 in SDC-4). 
 
Beyond the 1-month time point, MCC-TT-primed participants had significantly higher 
MenC SBA GMTs than those MCC-CRM-primed if boosted with MenACWY-TT 
(p=0.01) but not MenACWY-CRM (p=0.50). Pooling together the 6 month and 9 
month post booster time points the SBA GMTs for Menjugate, Meningitec and 
NeisVac-C were 983, 583, and 2702, respectively, for teenagers boosted with 
MenACWY-TT; compared to 2139, 2323, and 3128 for those boosted with 
MenACWY-CRM (see Table S3 in SDC-5). Overall this meant that Novartis 
MenACWY-CRM vaccine gave significantly higher MenC titers than MenACWY-TT 
(p=0.02, adjusted for primary vaccination and time since vaccination) (1.97-fold 
difference, 95% CI 1.10 – 3.53). 
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Post-boost serology for other antigens: For MenA, one month after booster, 
MenACWY-CRM induced significantly higher SBA titers than MenACWY-TT (Table 
1) (p=0.02, adjusted for primary vaccination); but this difference was not significantly 
sustained at further follow-up. MenW and MenY antibodies did not differ significantly 
between booster vaccine groups or by other comparisons (Tables 1-4 and Figure 3 
b-d). Understandably, only MenACWY-TT increased tetanus IgG levels while 
MenACWY-CRM boosted diphtheria antibody (see SDC-6 (Table S4), and SDC-7 
(Table S5)). 
 
Kinetics: Antibody decline over time was modelled as log-titer against log-time, for 
both SBA (Figure 4) and IgG (see SDC-8 (Figure S2)). Fold change in SBA titers as 
time doubles (beyond day 28) was estimated at 0.57 for MenC (95% CI 0.53-0.62), 
and 0.63 for Men W (0.58-0.69); both declining more rapidly than Men A, 0.84 (0.79-
0.91) and Men Y, 0.80 (0.75-0.85). 
 
Tolerability and safety: None of four serious adverse events (SAE) was 
investigator-assessed as causally vaccine-related. Of three that occurred in the 
MenACWY-CRM group, one was an incident case of ulcerative colitis onset ~20 
weeks after vaccination, and was stably managed as an out-patient. The other two 
involved brief hospitalisation (one for transient disorientation following suspected 
spiked social drinks, and the other for severe tonsillitis); both fully recovered. The 
only SAE in the GSK MenACWY-TT group was a hospital-treated case of 
appendicitis. No participant withdrew from the study, but two were lost to follow-up 
(Figure 1). Participant diary-reported solicited symptoms  indicated an overall similar 
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level of reactogenicity between the booster vaccines. The more severe grades of 
reactions were generally rare, although some appeared to be more often reported 
with either MenACWY-CRM (redness and muscle pain) or MenACWY-TT 
(tiredness). 
 
 
DISCUSSION 
Key findings: This study compared meningococcal serogroup-specific responses to 
two (CRM or TT-conjugated) MenACWY booster vaccines, in teenagers who had 
been primed with a CRM or TT-conjugated MCC vaccine at 3-6 years of age. The 
primary objective was to examine the relationships between childhood priming and 
teenage boosting with the different meningococcal antigen carrier proteins used in 
UK-licensed vaccines. Both booster vaccines induced high SBA levels against all 
four serogroups which were sustained through 9-month follow-up, demonstrating for 
the first time that either CRM or TT-conjugated MenACWY vaccines induce lasting 
protective immune responses in teenagers primed at pre-school age, regardless of 
the primary MCC vaccine received. In a persistent interaction effect, MenACWY-TT 
stimulated higher MenC SBA titers in those primed with MCC-TT than MCC-CRM-
primed individuals. At follow-up, MenACWY-CRM elicited significantly higher MenC 
antibody titers after adjusting for primary vaccine and time since vaccination. Given 
the strong and persistent responses to both vaccines, the post-booster differences 
may not be important for effectiveness. Secondarily, this study also enabled 
observation of novel long-term MenC post-primary antibody persistence data at 12-
14 years after pre-school priming, providing possibly the lengthiest primary 
persistence estimates available for this age-group. 
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Vaccine carrier protein influence: In our original pre-school study, MCC-TT was 
the most immunogenic primary vaccine (12), and MCC-TT-primed individuals in the 
current study had significantly higher SBA titers prior to boosting. For those primed 
with either of the two MCC-CRM vaccines, the composite (Menjugate® plus 
Meningitec®) proportion that still retained seroprotection before boosting was 32% 
(95%CI 21-46%), notably consistent with a UK serosurvey finding that 31.7% (23-
42%) of those eligible for single-dose (mainly MCC-CRM)  “catch-up” vaccination in 
England at toddler/preschool age had protective SBA titer after a decade (19). 
Following booster vaccination, individuals who were both primed and boosted with a 
TT-conjugated vaccine had significantly higher post-boost SBA titers, whereas those 
primed with MCC-CRM responded equally to either booster. Previous studies of 
meningococcal vaccine boosting in teenagers have not been specifically designed to 
investigate priming and boosting with different carrier protein-conjugated vaccines. 
Rather, participants were both primed and boosted with the same conjugate; either 
MCC-CRM (20, 21) or MCC-TT (22). In the USA, only MenACWY-CRM or 
MenACWY-D (Menactra®, a diphtheria-based conjugate vaccine) are licensed and 
routinely recommended for both primary vaccination at age 11-12 years and booster 
at 16 years (23). Thus recent USA studies have mostly focused on CRM-conjugated 
rather than TT-conjugated vaccines (24, 25). 
 
Postulations to explain the higher booster responses associated with TT-conjugated 
priming (9, 11) include the suggestion that MCC-TT is inherently superior to MCC-
CRM for primary vaccination (26) regardless of the booster vaccine-carrier 
combination, possibly because the de-O-acetylated polysaccharide of NeisVac-C® is 
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more immunogenic than the O-acetylated alternative (27). This might explain why 
Menitorix® (O-acetylated) boosting induces protective MenC responses in more 
NeisVac-C®–primed than Menitorix®-primed children (11). Our data support neither 
the proposal that CRM-conjugated vaccines have inherently diminished 
immunogenicity (28); nor that priming and boosting with the same carrier protein is 
superior to priming and boosting with different carrier proteins (9). 
 
Post-booster and post-primary persistence: Post-booster kinetic analysis of 
MenC antibody persistence showed ~40% decline in antibody as time doubles, 
contrasting with two-thirds decline previously observed in children given Hib-MCC-
TT booster in the second year of life (9). Our analysis of decline in antibody titre with 
time was limited by the small sample size of the study, particularly as the intended 
target size was not obtained due to the restricted pool of original study participants 
that could be recruited. Notwithstanding, our findings are compatible with other data 
indicating shorter antibody persistence after vaccination in younger relative to older 
age-groups (19, 29). Others have, however, estimated a slower annual 23% decline 
(95%CI 15-30) in odds of protection after Meningitec® vaccination at age 13-45 
months (30). 
 
This study also provided long-term (12-14 years) post-primary antibody persistence 
data in individuals primed at pre-school age. Approximately one-third to one-half of 
participants (depending on primary vaccine) were still putatively seroprotected, with 
significantly higher pre-boost MenC titers in those primed with MCC-TT. The age at 
primary vaccination may be crucial for the differential effect, as 5-year persistence 
after priming in older age cohorts (6-15 years) did not significantly differ between TT 
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and CRM-conjugated MCC vaccine groups (29). Previous studies of post-primary 
persistence in teenagers did not compare different vaccine carrier proteins and 
involved cohorts that were primed at older ages (≥9 years) (17, 20) or younger (1-3 
years) (30) (and therefore with different immunologic backgrounds) than our 
participants. Similar to the post-booster analysis, there are limitations in our primary 
persistence data as only a modest proportion of the original trial cohort could be 
included in this study, given the practical challenges of recruiting teenage 
participants from a previous childhood study of over a decade earlier. A third of the 
original group could not be contacted as they were no longer registered with local 
services or their records were inaccessible. But from the remainder we obtained a 
distinctive study group who provided a unique opportunity to gain new information on 
long-term persistence and booster responses given different meningococcal vaccine 
carrier proteins. 
 
Booster vaccine policy: Our data address current policy considerations in the UK. 
The Joint Committee on Vaccination and Immunisation in 2012 recommended 
routine adolescent MCC booster vaccination, but cautioned that “a serogroup Y-
containing meningococcal vaccine should only be used if the available vaccines do 
not compromise the response to meningococcal C” (14). We observed no such 
compromise, as most participants achieved protective and persistent antibody levels 
against all serogroups. MenACWY-CRM induced significantly higher MenA SBA 
GMT, possibly because of its much higher MenA antigen content. Moderate recent 
increases in MenW (13) and MenY (13, 31) infection in England are noted, and 
important local MenW transmission linked with imported infection has previously 
been documented (32). 
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Conclusion: Both MenACWY vaccines stimulated protective functional antibody 
titers against all serogroups in 16-19 year olds primed over a decade earlier, 
regardless of the primary MCC vaccine received. Individuals primed and boosted 
with TT-conjugated vaccine had higher MenC SBA titers, but overall titers were 
higher with MenACWY-CRM. Childhood MCC vaccine priming followed by teenage 
MenACWY boosting could be a suitable option to broaden meningococcal protection 
without compromise to MenC population immunity in the UK. 
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FIGURE LEGENDS 
Figure 1. Study participants and progression flow chart (CONSORT diagram). 
 
Figure 2. Comparison of post-primary and pre-boost MenC SBA titres: 
Meningococcal group C (MenC) serum bactericidal antibody (SBA) titers after the 
original primary vaccination at preschool age (post-primary, x-axis); compared with 
MenC SBA titers ≥12 years later (measured immediately before teenage booster 
vaccination) (pre-boost, y-axis).  Correlation between post-primary and pre-boost 
titers, r=0.45, n=41 (all teenagers who had MenC SBA results from the original 
study); or r=0.57, n=39 (excluding the two individuals who had post-primary titers <8 
in the original study). 
 
Figure 3. Serogroup-specific meningococcal serum bactericidal antibody (SBA); 
before and 1 month after boosting with quadrivalent TT or CRM-conjugated 
MenACWY vaccines, in teenagers who were primed in childhood with either a TT or 
CRM-conjugated meningococcal C conjugate (MCC) vaccine. Bars represent 
different combinations of vaccines (primary / booster); error bars represent 95% CI. 
The horizontal axis labels indicate the various combinations of prime and booster 
vaccines received. Priming vaccines: Menjugate® (MCC-CRM, labelled as C-CRM 1); 
Meningitec® (MCC-CRM, labelled as C-CRM 2); or NeisVac-C® (MCC-TT, labelled as C-
TT). Booster vaccines: MenACWY-CRM (Menveo®, Novartis, labelled as ACWY-CRM) or 
MenACWY-TT (Nimenrix®, GSK, labelled as ACWY-TT). Panels (from the top): Upper 
panel: MenC. Second from the top: MenW. Third from the top: MenA. Lower 
panel: MenY. 
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Figure 4: Decline in titers of serogroup-specific meningococcal (MenA, MenC, 
MenW, or MenY) serum bactericidal antibody (SBA) over time, after teenage booster 
vaccination, with fitted trend lines. Fold IgG titer changes per doubling times from 
day 28 (and 95% CI) estimated from a fixed effects model were as follows: Upper 
left panel: MenC 0.57 (0.53-0.62); upper right panel: MenW 0.63 (0.58-0.69); 
lower left panel: MenA 0.84 (0.79-0.91); and lower right panel: MenY 0.80 (0.75-
0.85). 
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Table 1: Serogroup-specific serum bactericidal antibody pre and post-booster vaccination, by primary vaccine 
   Proportion with SBA titer ≥8 (95% CI) SBA geometric mean titers (GMT) (95% CI) 
 
n 
Pre 
boost 
1 month post-boost 
6 months 
post-
boost 
9 months 
post-
boost 
Pre boost 1 month post-boost 
6 months 
post-boost 
9 months 
post-boost 
 
Primary 
vaccine 
Pre-
boo
st 
1 month 
post-
boost 
6 months 
post-
boost 
9 months 
post-
boost 
% ≥8 % ≥8 
% ≥4-fold 
SBA 
% ≥8 % ≥8 GMT GMT (n-fold) rise GMT GMT 
Men 
C 
Menjugate 33 33 16 17 24 
(11-42) 
100  
(89-100) 
100  
(89-100) 
100  
(79-100) 
94  
(71-100) 
5  
(3-10) 
8366 
(5430-12889) 
1592 
(870-2914) 
2896  
(1609-5214) 
739  
(269-2027) 
Meningitec 26 26 13 12 42 
(23-63) 
100  
(87-100) 
100  
(87-100) 
92  
(64-100) 
100  
(74-100) 
10  
(4-22) 
 
7562 
(4288-13336) 
764 
(386-1511) 
971  
(278-3390) 
1085  
(495-2378) 
NeisVac-C 34 33 16 17 53  
(35-70) 
100  
(89-100) 
97  
(84-100) 
100  
(79-100) 
100  
(80-100) 
26  
(10-64) 
15064 
(9294-24414) 
659 
(230-1885) 
3922  
(2391-6434) 
2222  
(1367-3613) 
A Menjugate 33 33 16 17 39  
(23-58) 
100  
(89-100) 
97  
(84-100) 
100  
(79-100) 
100  
(80-100) 
22  
(7-67) 
7532 
(5040-11256) 
336 
(113-997) 
5547 
 (3791-8117) 
3341  
(1438-7761) 
Meningitec 26 26 12 12 27  
(12-48) 
100  
(87-100) 
92  
(75-99) 
100  
(74-100) 
100  
(74-100) 
11  
(4-32) 
7767 
(4769-12648) 
724 
(221-2376) 
3251 
 (1681-6287) 
5793  
(3350-
10015) 
NeisVac-C 34 33 16 17 32  
(17-51) 
100  
(89-100) 
85  
(68-95) 
100  
(79-100) 
100  
(80-100) 
15  
(5-41) 
7532 
(4883-11618) 
471 
(143-1551) 
5793 
 (3562-9420) 
3932 
 (2136-7240) 
W Menjugate 33 33 16 17 6  
(1-20) 
100  
(89-100) 
100  
(89-100) 
94  
(70-100) 
100  
(80-100) 
2  
(2-3) 
8366 
(5579-12545) 
3462 
(1978-6061) 
1722 
 (588-5045) 
2222 
 (1129-4374) 
Meningitec 26 26 11 12 15  
(4-35) 
100  
(87-100) 
96  
(80-100) 
100  
(72-100) 
100  
(74-100) 
4  
(2-11) 
9613 
(6728-13735) 
2160 
(858-5438) 
1162 
 (471-2867) 
2299 
 (1205-4386) 
NeisVac-C 34 33 16 16 12  
(3-27) 
100  
(89-100) 
100  
(89-100) 
94  
(70-100) 
100  
(79-100) 
3  
(2-6) 
7222 
(5174-10081) 
2091 
(1277-3426) 
1722 
 (569-5215) 
2435  
(1432-4142) 
Y Menjugate 33 33 16 17 9  
(2-24) 
100  
(89-100) 
97  
(84-100) 
100  
(79-100) 
100  
(80-100) 
3  
(2-5) 
4745 
(3453-6520) 
1526 
(764-3051) 
3158 
 (1758-5675) 
2222 
 (1466-3367) 
Meningitec 26 26 13 12 12  
(2-30) 
100  
(87-100) 
100  
(87-100) 
92  
(64-100) 
100  
(74-100) 
4  
(2-8) 
5640 
(3789-8395) 
1448 
(593-3538) 
1410 
 (462-4306) 
2580  
(1609-4139) 
NeisVac-C 34 33 16 17 21  
(9-38) 
97  
(84-100) 
91  
(76-98) 
94  
(70-100) 
100  
(80-100) 
6  
(3-14) 
2927 
(1588-5396) 
471 
(172-1291) 
1166 
(396-3437) 
2222  
(1200-4113) 
Primary vaccines: Menjugate®; Meningitec® (both MCC-CRM); NeisVac-C® (MCC-TT).  
Table
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Table 2: Serogroup-specific serum bactericidal antibody pre and post-booster vaccination, by booster vaccine 
 
 
    Proportion with SBA titer ≥8 (95% CI) SBA geometric mean titers (GMT) (95% CI) 
 n 
Pre 
boost 
1 month post-boost 
6 months 
post-
boost 
9 months 
post-
boost 
Pre 1 month post-boost 
6 months 
post-boost 
9 months 
post-boost 
 
Booster 
vaccine 
Pre-
boost 
1 
month 
post-
boost 
6 
months 
post-
boost 
9 
months 
post-
boost 
% ≥8 % ≥8 
% 
≥4-fold 
% ≥8 % ≥8 GMT GMT (n-fold) rise GMT GMT 
Men C                
 MenACWY-
TT 
46 46 21 25 30  
(18-46) 
100  
(92-100) 
98  
(88-100) 
95  
(76-100) 
96  
(80-100) 
7 
(4-13) 
8701 
(6008-12601) 
1209 
(631-2315) 
1208 
(565-2581) 
1082 
(562-2084) 
MenACWY-
CRM 
47 46 24 21 49  
(34-64) 
100  
(92-100) 
100  
(92-100) 
100  
(86-100) 
100  
(84-100) 
17 
(9-35) 
11585 
(7560-17753) 
735 
(371-1457) 
4216 
(2727-6518) 
1424 
(737-2753) 
A                
 ACWY-TT 46 46 21 25 30  
(18-46) 
100  
(92-100) 
91  
(79-98) 
100  
(84-100) 
100 
(86-100) 
13 
(6-30) 
5706 
(4003-8134) 
440 
(177-1095) 
4096 
(2715-6180) 
3191 
(1741-5852) 
ACWY-CRM 47 46 23 21 36  
(23-51) 
100  
(92-100) 
91  
(79-98) 
100  
(85-100) 
100  
(84-100) 
19 
(8-47) 
10116 
(7314-13992) 
504 
(194-1308) 
5706 
(3894-8361) 
5513 
(3468-8762) 
W                
 ACWY-TT 46 46 21 24 7  
(1-18) 
100  
(92-100) 
100  
(92-100) 
100  
(84-100) 
100  
(86-100) 
3 
(2-4) 
8967 
(6733-11943) 
3170 
(1997-5032) 
1795 
(989-3255) 
2299 
(1460-3620) 
ACWY-CRM 47 46 22 21 15  
(6-28) 
100  
(92-100) 
98  
(88-100) 
91  
(71-99) 
100  
(84-100) 
4 
(2-6) 
7597 
(5586-10333) 
2017 
(1145-3555) 
1360 
(492-3754) 
2337 
(1370-3985) 
Y                
 ACWY-TT 46 46 21 25 17  
(8-31) 
100  
(92-100) 
100  
(92-100) 
95  
(76-100) 
100  
(86-100) 
5 
(3-8) 
4484 
(3555-5655) 
964 
(492-1888) 
1522 
(759-3050) 
2353 
(1641-3372) 
ACWY-CRM 47 46 24 21 11  
(4-23) 
98  
(88-100) 
91  
(79-98) 
96  
(79-100) 
100  
(84-100) 
4 
(2-7) 
3915 
(2390-6414) 
1009 
(468-2175) 
1990 
(896-4419) 
2261 
(1412-3622) 
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Table 3: Seroroup-specific IgG pre and post-booster vaccination, by booster vaccine 
 
 
IgG geometric mean concentrations (GMC) (ug/mL) (95% CI) 
 Pre-boost 1 month post-boost 6 months post-boost 9 months post-boost 
 Booster vaccine n GMC n GMC 
(n-fold) rise in 
GMC 
n GMC n GMC 
Men C 
 
          
MenACWY-TT 46 0.2 (0.2-0.3) 46 15.0 (10.9-20.4) 62.4 (42.9-90.6) 21 3.9 (2.5-6.1) 25 2.4  (1.7-3.5) 
MenACWY-CRM 47 0.4 (0.3-0.5) 46 20.2 (15.9-25.7) 56.2 (37.6-84) 24 6.8 (4.6-9.9) 21 2.6  (1.6-4.2) 
A 
 
          
MenACWY-TT 46 1.8 (1.3-2.6) 46 27.7 (17.1-44.6) 15 (10.1-22.1) 21 6.0 (2.9-12.6) 24 7.0  (3.6-13.5) 
MenACWY-CRM 47 1.3 (1.0-1.7) 46 44.1 (30.1-64.4) 34.2 (25.4-46.1) 24 17.5 (8.0-38.5) 21 9.1 (4.7-17.8) 
W 
 
          
MenACWY-TT 46 0.7 (0.5-1.0) 46 19.4 (13.7-27.4) 26.3 (18.1-38.3) 21 5.7  (2.9-11.4) 25 6.2 (4.1-9.3) 
MenACWY-CRM 47 0.7 (0.5-1.1) 46 16.9 (11.2-25.5) 23.6 (14.9-37.3) 23 4.8  (2.4-9.6) 21 4.1  (2.1-8.1) 
Y 
 
          
MenACWY-TT 46 1.2 (0.9-1.6) 46 13.2 (9.0-19.4) 11.2 (8.1-15.5) 21 7.1  (3.8-13.4) 24 5.4  (3.3-9.0) 
MenACWY-CRM 47 0.8 (0.6-1.0) 46 9.0 (5.7-14.3) 11.6 (7.6-17.9) 22 3.8  (2.1-6.9) 21 5.0  (2.2-11.0) 
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Table 4: Serogroup-specific IgG pre and post-booster vaccination, by primary vaccine and across all study groups 
   IgG geometric mean concentrations (GMC) (ug/mL) (95% CI) 
 Booster 
vaccine 
Primary 
vaccine 
Pre-boost 1 month post-boost 6 months post-boost 9 months post-boost 
 n GMC n GMC n-fold rise in GMC n GMC n GMC 
Men C All Menjugate 33 0.3   (0.2-0.4) 33 17.3   (12.4-24.1) 63.3 (44.3-90.4) 16 6.4 (3.7-11.2) 17 2.3 (1.4-3.8) 
 Meningitec 26 0.3   (0.2-0.4) 26 13.7   (9.1-20.7) 51.4 (32.6-81.0) 13 2.8 (1.6-5.1) 12 2.3 (1.1-4.9) 
 Neisvac-C 34 0.4   (0.2-0.6) 33 21.1   (15.4-28.8) 61.9 (34.2-111.8) 16 7.0 (4.8-10.1) 17 2.8 (1.9-4.2) 
 MenACWY
-TT 
Menjugate 17 0.3   (0.2-0.4) 17 13.5   (8.1-22.6) 49.5 (29.8-82) 8 4.6 (2.2-9.8) 9 2.4 (1.4-4.1) 
 Meningitec 14 0.2   (0.1-0.5) 14 11.7   (6.3-21.7) 46.9 (25.2-87.3) 7 2.1 (0.8-5.5) 7 2.8 (0.9-8.8) 
 Neisvac-C 15 0.2   (0.1-0.4) 15 21.1   (11.7-38.1) 105.8 (44.4-252.2) 6 6.4 (2.9-14.2) 9 2.2 (1.2-4.0) 
 MenACWY
-CRM 
Menjugate 16 0.3   (0.1-0.5) 16 22.4   (14.5-34.6) 82.3 (48.4-139.7) 8 8.9 (3.5-22.7) 8 2.2 (0.8-6.5) 
 Meningitec 12 0.3   (0.2-0.4) 12 16.6   (9.1-30.5) 57.1 (26.3-124.0) 6 4.1 (1.7-9.9) 5 1.8 (0.4-7.2) 
 Neisvac-C 19 0.6   (0.3-1.1) 18 21.0   (14.6-30.1) 39.6 (17.3-90.2) 10 7.4 (4.5-12.1) 8 3.8 (2.1-6.7) 
A All Menjugate 33 1.8   (1.3-2.5) 33 51.1   (31.8-82.2) 28 (18.0-43.4) 16 24.1 (12.1-47.8) 17 8.9 (3.9-20.5) 
 Meningitec 26 1.2   (0.8-1.9) 26 18.6   (9.9-35.1) 15.0 (9.4-23.7) 12 4.2 (1.1-15.3) 12 4.1 (1.9-8.8) 
 Neisvac-C 34 1.5   (1.0-2.3) 33 39.1   (24.0-63.8) 25.4 (16.2-39.7) 16 10.1 (4.1-24.7) 17 11.6 (5.2-25.7) 
 MenACWY
-TT 
Menjugate 17 2.3   (1.4-3.8) 17 41.0   (18.3-91.7) 17.7 (8.4-37.5) 8 15.2 (5.5-42.2) 9 7.3 (2.1-25.4) 
 Meningitec 14 1.4   (0.8-2.7) 14 14.5   (5.6-37.7) 10.2 (5.4-19.1) 7 4.0 (0.5-29.7) 7 2.8 (1.3-5.9) 
 Neisvac-C 15 1.8   (0.8-4.0) 15 32.4   (13.8-76.0) 17.7 (8.4-37.4) 6 2.8 (1.4-5.6) 9 15.2 (3.7-61.8) 
 MenACWY
-CRM 
Menjugate 16 1.4   (1.0-2.1) 16 64.6   (36.9-113.1) 45.3 (30.5-67.4) 8 38.1 (13.4-108.8) 8 11.2 (2.8-45.7) 
 Meningitec 12 1.1   (0.6-2.0) 12 25.0   (9.8-63.9) 23.6 (12.0-46.1) 5 4.4 (0.4-50.4) 5 6.9 (1.0-48.4) 
 Neisvac-C 19 1.3   (0.8-2.1) 18 45.7   (24.5-85.4) 34.2 (19.4-60.2) 10 21.7 (6.6-70.8) 8 8.9 (2.9-27.3) 
W All Menjugate 33 0.6   (0.4-1.0) 33 18.7   (12.6-27.7) 30.2 (17.6-51.7) 16 6.2 (3.1-12.5) 17 4.7 (2.6-8.4) 
 Meningitec 26 0.7   (0.5-1.0) 26 13.6   (8.0-23.3) 20.2 (10.6-38.4) 12 2.0 (0.8-5.1) 12 3.6 (1.9-6.8) 
 Neisvac-C 34 0.9   (0.5-1.4) 33 21.9   (13.3-35.9) 24.3 (16.3-36.0) 16 8.9 (3.8-20.8) 17 7.4 (3.5-15.4) 
 MenACWY
-TT 
Menjugate 17 0.8   (0.4-1.6) 17 17.3   (10.9-27.4) 21.8 (10.9-43.5) 8 4.2 (1.7-10.6) 9 6.6 (2.9-15.0) 
 Meningitec 14 0.7   (0.5-1.0) 14 14.9   (7.5-29.8) 21.6 (9.9-47.3) 7 2.7 (0.9-8.3) 7 4.9 (2.4-10.2) 
 Neisvac-C 15 0.7   (0.4-1.4) 15 28.0   (13.0-60.4) 39.2 (22.1-69.5) 6 20.2 (3.4-120.9) 9 6.9 (2.9-16.7) 
 MenACWY
-CRM 
Menjugate 16 0.5   (0.2-1.0) 16 20.3   (10.0-41.3) 42.7 (17.7-102.9) 8 9.1 (2.7-31.2) 8 3.1 (1.2-8.4) 
 Meningitec 12 0.7   (0.3-1.5) 12 12.2   (4.7-31.8) 18.7 (5.6-61.8) 5 1.3 (0.1-12.7) 5 2.2 (0.5-10.3) 
 Neisvac-C 19 1.0   (0.5-2.1) 18 17.8   (8.8-35.9) 16.3 (9.7-27.4) 10 5.5 (2.1-14.6) 8 7.8 (1.8-34.9) 
Y All Menjugate 33 1.1   (0.8-1.6) 33 13.8   (8.6-22.1) 12.6 (7.8-20.5) 16 10.4 (5.3-20.4) 17 4.8 (2.3-10.1) 
 Meningitec 26 0.8   (0.5-1.1) 26 7.3   (4.2-12.6) 9.5 (5.7-15.9) 11 2.5 (0.8-7.5) 12 2.6 (1.4-4.8) 
 Neisvac-C 34 1.0   (0.7-1.5) 33 11.9   (6.8-20.7) 11.9 (7.7-18.3) 16 4.2 (2.4-7.3) 16 9.4 (3.9-22.6) 
 MenACWY
-TT 
Menjugate 17 1.1   (0.6-1.9) 17 12.1   (7.0-20.8) 11.2 (6.4-19.6) 8 10.7 (3.1-37.1) 9 2.8 (1.9-4.1) 
 Meningitec 14 1.0   (0.6-1.6) 14 8.2   (3.9-17.4) 8.4 (4.2-16.6) 7 3.1 (0.8-12.2) 7 4.4 (1.9-10.5) 
 Neisvac-C 15 1.5   (0.8-3.1) 15 22.7   (10.3-50.1) 14.7 (8.3-26.1) 6 11.0 (5.0-24.0) 8 13.4 (3.9-46.5) 
 MenACWY
-CRM 
Menjugate 16 1.1   (0.7-1.9) 16 15.8   (6.8-37.1) 14.4 (6.0-34.3) 8 10.1 (4.0-25.4) 8 8.8 (1.8-43.7) 
 Meningitec 12 0.6   (0.3-1.0) 12 6.3   (2.4-16.1) 11.0 (4.4-27.2) 4 1.7 (0.1-46.0) 5 1.3 (0.9-1.8) 
 Neisvac-C 19 0.7   (0.4-1.1) 18 6.9   (3.3-14.6) 10 (5.1-19.5) 10 2.4 (1.4-4.0) 8 6.6 (1.5-30.0) 
Primary vaccines: Menjugate®; Meningitec® (both MCC-CRM); NeisVac-C® (MCC-TT). 
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Booster vaccine group 
(provided pre-boost blood 
sample and  received 
allocated booster) 
MenACWY-TT (GSK) 
n = 46 
 
MenACWY-CRM (Novartis) 
n = 47 
Priming vaccine received  
(during original study) 
(MCC-CRM) 
Menjugate® 
n=17 
(MCC-CRM) 
Meningitec® 
n=14 
(MCC-TT) 
NeisVac-C® 
n=15 
 
(MCC-CRM) 
Menjugate® 
n=16 
(MCC-CRM) 
Meningitec® 
n=12 
(MCC-TT) 
NeisVac-C® 
n=19 
Provided 1-month post-boost 
blood sample 
n=17 14 15  n=16 12 
18 
(1 lost to 
follow-up; 
relocated) 
Provided final post-boost 
blood sample 
(All included in analysis) 
n=17 14 15  n=16 
11 
(1 lost to 
follow-up; 
loss of 
contact) 
18 
Original study:  
MCC-CRM (Menjugate® or Meningitec®) or MCC-TT (NeisVac-C®) primary vaccination of children aged 3.5-5.9 years (n=832) 
Unable to trace (n=217) 
- Preliminary check on the health service 
demographics system indicated no longer 
registered for services in the study areas 
Randomised: teenagers aged 16-19 years (n=93) 
For this study: 
GP (family doctor) records checked to confirm if original study participants still on local health service registers (n=615) 
Confirmed as still on health service registers in study areas; available for invitation to join this study (n=558) 
Unable to confirm if still on local registers (n=57) 
- GPs unable to check records 
Excluded (n=465) 
- Did not respond to study invitation (n=456) 
- Responded late, after recruitment (n=1) 
- Declined to participate (n=2) 
- Did not meet inclusion criteria (n=6) 
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SUPPLEMENTAL DIGITAL CONTENT – METHODS 
Participants: From the original cohort of 832 pre-school age children who took part in a 
previous study between 1998 and 2000, a preliminary check on the health service 
demographics system suggested that 615 were still registered with GPs for health services 
in Hertfordshire and Gloucestershire, England (see Figure 1 in main article). Study vaccine 
research nurses and partners from the regional primary care research network (PCRN) 
contacted GPs to check their records. For 57 individuals, the records were inaccessible as 
GP configurations had either changed or their GPs were not able to participate in the 
checking process. Those who were confirmed to still be registered were invited to join this 
study, and eligible respondents were enrolled after providing fully informed written consent. 
Teenagers who received an MCC vaccine during the preschool study, but no further MCC 
vaccination thereafter, and no other vaccine within the 3 months preceding enrolment, were 
included. Exclusion criteria included immunosuppression, pregnancy, significant medical 
illness, antibiotic use within 14 days of enrolment, previous confirmed invasive 
meningococcal disease, and any other contraindication as per routine practice guidelines in 
the UK national immunisation guidance “Green Book”1. Study formal procedures 
commenced in June 2012 and recruitment took place between July and November 2012. 
For antibody persistence measurements, participants were randomised in order of inclusion 
                                                          
1 Department of Health, England. Meningococcal meningitis and septicaemia (Updated 11 
April 2014). In: Salisbury D, Ramsay M, eds. Immunisation against infectious disease: the 
Green Book (chapter 22). London: Crown copyright 2013; Open Government Licence v 2.0. 
URL: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/302904/Gree
n_Book_Chapter_22_v2_5.pdf (accessed 14 August 2014). 
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using a computer-generated list, to either 6 or 9 months follow-up, with final study visits in 
August 2013. Participants completed a health diary to record oral temperature and any local 
or systemic reactions daily for the week following vaccination. Reactions and events were 
further monitored by vaccine research nurses during a telephone follow-up on the 8th day 
post-vaccination; and by directly enquiring from participants at each study visit. 
Regulation: The trial was approved by the North West 3 NHS Research Ethics Committee 
(Reference 11/H1002/6) and conducted in accordance with the Helsinki Declaration (2008 
amendment), the 1996 International Committee for Harmonisation Guidelines for Good 
Clinical Practice, and the 2004 EU Clinical Trial Directive. The supplementary section 
provides further information on participants, regulation, vaccines, serology, and analyses. 
After gaining all regulatory approvals, appropriate local research governance permissions 
in Hertfordshire and Gloucestershire were obtained. The trial EudraCT Number is 2010-
022505-18. It was registered on the public website, www.ClinicalTrials.gov (identifier 
NCT01192997), and adopted and registered on the National Institute for Health Research 
(NIHR) Clinical Research Network (CRN) Portfolio database (ID 10242). 
 
Vaccines: Novartis MenACWY (Menveo®) was licensed by the European Medicine Agency 
(EMeA) in 2009, and currently indicated for use from 2 years of age and above. It has 10 µg 
of MenA oligosaccharide; and 5 µg of each of MenC, W and Y, with a total 
Corynebacterium diphtheriae CRM197 protein content of 32.7-45.8 μg per dose. GSK 
MenACWY was an investigational product during preparation for this study. It became 
licensed 2 (as Nimenrix®) just before study commencement, but the already provided pre-
                                                          
2 European Medicines Agency (2012). EPAR-summary for the public: Nimenrex 
(EMA/CHMP/136315/2012). URL: 
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licensure batch was used. It had 5 μg oligosaccharide of each of the four serogroups, and a 
total tetanus toxoid content of ~44 μg per dose. 
 
Serology: After blood sample collection, sera were separated and testing for tetanus and 
diphtheria antitoxin performed at Public Health England (PHE) Microbiology Services 
laboratories at Porton Down; aliquots were transported on dry ice to the PHE Vaccine 
Evaluation Unit, Manchester, for meningococcal antibody measurements. Laboratory staff 
remained unaware of participants’ study groups. Sera were tested for serogroup-specific 
IgG antibodies using a standardised enzyme-linked immunosorbent assay (ELISA) 
protocol. They were tested for serogroup-specific SBA using a standardized assay 
incorporating serum from 3-4 week old rabbits as the exogenous complement source. The 
target meningococcal strains used were MenC C11, MenW M01.240070, and MenY 
M00.241125 (S1975), MenA M99.243594. SBA titers were expressed as the reciprocal 
serum dilutions yielding ≥50% killing after 60 min. Diphtheria and tetanus-specific 
antibodies (IgG) were quantified using standardized ELISAs with the National Institute for 
Biological Standards and Control (NIBSC) National Diphtheria reference serum 00/496 and 
the first International Tetanus reference serum 26/488. 
 
Statistics: Outcomes were measured at three time points; pre-booster, 28 days post-boost, 
and either 6 or 9 months post-boost. The proportion of participants with serogroup A, C, W 
and Y-specific SBA titers ≥8 and ≥128 (not shown); as well as SBA geometric mean titers 
(GMTs) were calculated with 95% confidence intervals (95% CIs) at each time point. 
                                                                                                                                                                                                   
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Summary_for_the_public/human/002226/WC500127665.pdf (accessed 14 August 2014) 
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Proportions with ≥4-fold rises in SBA titer from baseline (results not shown) and geometric 
mean (n-fold) rises in SBA titer from baseline were also calculated with 95% CIs. Similarly, 
serogroup-specific IgG geometric mean concentrations (GMCs) were calculated with 95% 
CIs at each time point, along with geometric mean rises (n-fold) in concentration from the 
baseline. For antibody responses to the vaccine carrier proteins, GMCs of antibody to TT 
and diphtheria toxin, as well as proportions with specific IgG concentration ≥0.1 IU/mL, 
were calculated with 95% CIs at each time point (CIs not shown). SBA titers below the 
lower detection limit of 4 were assigned a value of 2 for computational purposes, and 
antibody titers were log-transformed for geometric mean calculations. The 95% CIs were 
calculated for each of the groups as well as overall by the three primary vaccines and 
overall by the two trial vaccines. Comparisons between boosters and by primary 
vaccination overall were done at a 5% significance level. Post-boost measurements were 
compared by primary vaccine and by booster vaccine, with multivariable normal errors 
regression on logged antibody levels, adjusting for pre-vaccination titers and time from 
vaccination to blood sample, and testing for interactions. Previously-reported post-primary 
antibody responses from the original study were compared with pre-booster antibody 
responses from the current trial, by regression of logged post-primary (original study) titers 
on logged teenage (current study) pre-boost titers, taking account of between-group 
differences in primary vaccine and booster vaccine. Comparisons across the 6 arms were 
by non-overlapping 95% CIs, being a conservative approach (equivalent to a P < 0.01 
approximately) to allow for the high numbers of possible comparisons. 
 
SUPPLEMENTAL DIGITAL CONTENT – RESULTS 
The male/female distribution was 16 /30 (MenACWY-TT group) and 20/27 (MenACWY-
CRM group). The median 1, 6 and 9-month post-booster intervals to blood sampling were 
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27 (range 17-42), 273 (251-306), and 189 (161-231) days, respectively. All were included in 
analysis as they were within pre-set time point limits. Per-protocol analysis only was carried 
out since there was no difference to modified intention-to-treat data. For all antigen group 
comparisons, age and gender were not associated with responses and not included in the 
models. 
 
LEGENDS TO SUPPLEMENTAL FIGURES 
Supplemental Figure S1. Meningococcal group C serum bactericidal antibody (SBA) (upper 
panel, n=40) and IgG (lower panel, n=81). Antibody titers after the original primary vaccination with 
a meningococcal C conjugate vaccine at pre-school age (post-primary, x-axis), were compared to 
titers one month after teenage booster vaccination (1-month post-boost, y-axis). Trend lines were 
fitted. Regression of logged post-boost on post-primary titers, allowing for primary and booster 
vaccines, showed weakly positive association for both SBA and IgG, but neither reached statistical 
significance (SBA p=0.26; IgG p=0.09). 
 
Supplemental Figure S2. Decline in meningococcal serogroup-specific IgG titers over time, after 
teenage booster vaccination, with fitted trend lines. Fold titer changes per doubling time since day 
28 (and 95% CI) estimated from a fixed effects model were as follows: Upper left panel: MenC IgG 
0.61 (0.58-0.64); Upper right panel: MenW 0.67 (0.64-0.71); Lower left panel: MenA 0.66 (0.62-
0.7); and lower right panel: MenY 0.78 (0.74-0.82). 
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SUPPLEMENTAL DIGITAL CONTENT 2 – TABLE S1 
 
Supplemental digital content: Table S1: Characteristics of current study participants, compared with individuals 
from the original study cohort who did not participate in this study  
Factor  
Participants in current study 
(n=93) 
Non-participants in current study 
(n=739) 
p-value 
Mean age at time of primary vaccination, in years 4.32 4.28 0.21 
Number of males (percentage of total) 36 (38.7%) 385 (52.1%) 0.02 
Primary vaccine received in the 
original study 
Menjugate® 33 281 
0.77 Meningitec® 26 182 
NeisVac-C® 34 276 
Post-primary MenC antibody 
responses in the original study  
SBA GMT 
(95% CI) 
1114 (488-2542) [n=41] 1180 (965-1444) [n=376] 0.87 
IgG GMC, µg/mL  
(95% CI) 
8.75 (6.64-11.53) [n=82] 8.55 (7.74-9.43) [n=618] 0.87 
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SUPPLEMENTAL DIGITAL CONTENT 3 – TABLE S2 
 
 
Supplemental digital content: Table S2: Serogroup-specific serum bactericidal antibody (SBA) geometric mean titres (GMT) pre and 
post-booster vaccination, across all study groups 
   Pre boost 1 month post-boost 6 months post-boost 9 months post-boost 
 Booster vaccine 
Primary 
vaccine 
n GMT (95% CI) n GMT (95% CI) 
(n-fold) rise in 
GMT (95% CI) 
n GMT (95% CI) 
n 
 
GMT (95% CI) 
MenC MenACWY-TT Menjugate 17 5 (2-13) 17 6414 (3604-11417) 1205 (467-3109) 8 1448 (724-2895) 9 697 (129-3765) 
Meningitec 14 7 (2-20) 14 4752 (2527-8935) 689 (250-1899) 7 420 (45-3956) 7 689 (261-1816) 
NeisVac-C 15 11 (3-44) 15 21619 (12144-38484) 2048 (426-9837) 6 3251 (1795-5888) 9 2389 (1194-4780) 
MenACWY-CRM Menjugate 16 5 (2-14) 16 11094 (5580-22058) 2139 (937-4883) 8 5793 (2712-12370) 8 790 (173-3594) 
Meningitec 12 15 (4-57) 12 13004 (4786-35334) 861 (297-2496) 6 2580 (863-7714) 5 2048 (409-10247) 
NeisVac-C 19 51 (15-172) 18 11148 (5171-24034) 256 (64-1032) 10 4390 (1990-9682) 8 2048 (853-4918) 
MenA MenACWY-TT Menjugate 17 17 (3-79) 17 4822 (2651-8769) 289 (64-1307) 8 4467 (2515-7932) 9 1756 (382-8069) 
Meningitec 14 8 (2-31) 14 5513 (2746-11068) 724 (130-4035) 7 2756 (1046-7265) 7 4522 (2075-9854) 
NeisVac-C 15 16 (3-79) 15 7132 (3546-14344) 446 (67-2975) 6 5793 (2125-15788) 9 4424 (1796-10894) 
MenACWY-CRM Menjugate 16 31 (5-174) 16 12098 (7444-19663) 395 (68-2278) 8 6889 (3781-12550) 8 6889 (3781-12550) 
Meningitec 12 16 (2-109) 12 11585 (5667-23684) 724 (105-4983) 5 4096 (1050-15972) 5 8192 (2855-23506) 
NeisVac-C 19 14 (3-60) 18 7883 (4290-14483) 493 (90-2683) 10 5793 (2960-11336) 8 3444 (1191-9959) 
MenW MenACWY-TT Menjugate 17 3 (1-5) 17 8192 (4873-13772) 3079 (1219-7776) 8 2233 (1018-4901) 9 1896 (770-4670) 
Meningitec 14 3 (1-7) 14 11026 (6165-19718) 3710 (1267-10865) 7 840 (194-3643) 7 2756 (1219-6231) 
NeisVac-C 15 3 (2-5) 15 8192 (4956-13541) 2830 (1717-4665) 6 3251 (991-10663) 8 2435 (882-6724) 
MenACWY-CRM Menjugate 16 2 (2-3) 16 8555 (4274-17122) 3922 (1910-8055) 8 1328 (131-13468) 8 2656 (742-9503) 
Meningitec 12 7 (1-39) 12 8192 (5172-12977) 1149 (215-6154) 4 2048 (832-5040) 5 1783 (382-8313) 
NeisVac-C 19 4 (2-9) 18 6502 (3993-10587) 1625 (705-3750) 10 1176 (202-6848) 8 2435 (1240-4784) 
MenY MenACWY-TT Menjugate 17 3 (2-7) 17 4096 (2868-5850) 1205 (464-3135) 8 2048 (959-4374) 9 2212 (1125-4350) 
Meningitec 14 4 (1-14) 14 4993 (2871-8684) 1131 (260-4924) 7 1024 (102-10330) 7 2497 (1357-4594) 
NeisVac-C 15 7 (2-25) 15 4493 (2991-6749) 645 (162-2568) 6 1625 (898-2944) 9 2389 (1039-5495) 
MenACWY-CRM Menjugate 16 3 (1-6) 16 5547 (3132-9825) 1961 (648-5938) 8 4871 (1852-12813) 8 2233 (1163-4289) 
Meningitec 12 3 (1-11) 12 6502 (3362-12574) 1933 (612-6101) 6 2048 (1068-3925) 5 2702 (852-8575) 
NeisVac-C 19 5 (2-17) 18 2048 (684-6130) 362 (75-1739) 10 955 (153-5970) 8 2048 (643-6526) 
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SUPPLEMENTAL DIGITAL CONTENT 5 – TABLE S3 
Supplemental digital content: Table S3: MenC-specific serum 
bactericidal antibody (SBA) geometric mean titres (GMT): 
Composite 6 and 9-month post-booster data, by primary and booster 
vaccine, and across all study groups 
Booster vaccine Primary vaccine n GMT  (95 %CI) 
All Menjugate 33 1433 (777-2642) 
 Meningitec 25 1024 (511-2054) 
 NeisVac-C 33 2927 (2077-4124) 
GSK All 46 1138 (706-1834) 
Novartis All 45 2541 (1696-3806) 
MenACWY-TT Menjugate 17 983 (413-2342) 
 Meningitec 14 538 (189-1532) 
 NeisVac-C 15 2702 (1757-4156) 
MenACWY-CRM Menjugate 16 2139 (853-5363) 
 Meningitec 11 2323 (1102-4896) 
 NeisVac-C 18 3128 (1793-5456) 
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SUPPLEMENTAL DIGITAL CONTENT 6 – TABLE S4 
Supplemental digital content: Table S4: Tetanus antibody 
  Geometric mean concentrations (GMC) (IU/mL) (95% CI) 
  Pre-boost 1 month post-boost 6 months post-boost 9 months post-boost 
Primary vaccine Booster vaccine n GMC n GMC n GMC n GMC 
Menjugate All 33 1.04 (0.6-1.82) 32 3.85 (2.07-7.18) 16 2.68 (1.25-5.72) 17 1.8 (0.81-4.04) 
Meningitec All 25 0.93 (0.53-1.63) 25 3.8 (1.81-7.98) 11 3.1 (1.24-7.76) 12 1.44 (0.5-4.14) 
NeisVac-C All 33 1.76 (1.15-2.71) 32 4.89 (2.86-8.36) 16 3.07 (1.54-6.13) 17 3.46 (2.15-5.55) 
all MenACWY-TT 45 1.13 (0.73-1.76) 44 13.7* (10.2-18.4) 20 7.06 (4.61-10.83) 25 3.5 (2.14-5.73) 
all MenACWY-CRM 46 1.31 (0.88-1.96) 45 1.31 (0.88-1.95) 23 1.36 (0.82-2.24) 21 1.22 (0.63-2.37) 
Menjugate MenACWY-TT 17 0.88 (0.37-2.08) 16 11.66 (6.19-21.94) 8 6.73 (3.82-11.85) 9 2.07 (0.61-6.98) 
Meningitec MenACWY-TT 13 0.91 (0.45-1.83) 13 13.2 (7.38-23.6) 6 5.28 (1.52-18.31) 7 3.97 (1.85-8.53) 
NeisVac-C MenACWY-TT 15 1.82 (0.81-4.1) 15 16.8 (11.29-25) 6 10.09 (3.81-26.72) 9 5.4 (2.84-10.26) 
Menjugate MenACWY-CRM 16 1.24 (0.56-2.76) 16 1.27 (0.58-2.77) 8 1.06 (0.33-3.43) 8 1.55 (0.39-6.1) 
Meningitec MenACWY-CRM 12 0.95 (0.34-2.63) 12 0.98 (0.38-2.54) 5 1.64 (0.29-9.36) 5 0.35 (0.05-2.26) 
NeisVac-C MenACWY-CRM 18 1.72 (1.05-2.82) 17 1.65 (0.95-2.86) 10 1.5 (0.79-2.87) 8 2.09 (1.09-4) 
  Proportions ≥0.1 IU/mL 
  Pre-boost 1 month post-boost 6 months post-boost 9 months post-boost 
  n % ≥0.1 IU/mL n % ≥0.1 IU/mL n % ≥0.1 IU/mL n % ≥0.1 IU/mL 
Menjugate All 33 88 32 97 16 94 17 94 
Meningitec All 25 96 25 96 11 100 12 92 
NeisVac-C All 33 97 32 100 16 100 17 100 
all MenACWY-TT 45 91 44 100 20 100 25 96 
all MenACWY-CRM 46 96 45 96 23 96 21 95 
Menjugate MenACWY-TT 17 82 16 100 8 100 9 89 
Meningitec MenACWY-TT 13 100 13 100 6 100 7 100 
NeisVac-C MenACWY-TT 15 93 15 100 6 100 9 100 
Menjugate MenACWY-CRM 16 94 16 94 8 88 8 100 
Meningitec MenACWY-CRM 12 92 12 92 5 100 5 80 
NeisVac-C MenACWY-CRM 18 100 17 100 10 100 8 100 
*p<0.001 vs MenACWY-CRM, normal errors regression, adjusting for primary vaccine. 
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SUPPLEMENTAL DIGITAL CONTENT 7 – TABLE S5 
 
Supplemental digital content: Table S5: Diphtheria antibody 
  Geometric mean concentrations (GMC) (IU/mL) (95% CI) 
  Pre-boost 1 month post-boost 6 months post-boost 9 months post-boost 
Primary vaccine Booster vaccine n GMC n GMC n GMC n GMC 
Menjugate All 33 0.43 (0.25-0.73) 33 2.15 (0.9-5.18) 16 1.36 (0.46-4.01) 17 1.05 (0.36-3.05) 
Meningitec All 25 0.46 (0.27-0.81) 25 1.98 (0.74-5.28) 11 1.34 (0.34-5.22) 12 0.54 (0.18-1.63) 
NeisVac-C All 33 0.47 (0.3-0.72) 32 2.31 (0.99-5.37) 16 1.63 (0.56-4.71) 17 1.09 (0.44-2.69) 
all MenACWY-TT 45 0.29 (0.19-0.45) 45 0.28 (0.18-0.44) 20 0.33 (0.14-0.76) 25 0.24 (0.14-0.39) 
all MenACWY-CRM 46 0.7 (0.51-0.97) 45 16.38* (12.32-21.77) 23 5.24 (3.43-8.02) 21 4.36 (2.72-7) 
Menjugate MenACWY-TT 17 0.3 (0.13-0.68) 17 0.28 (0.12-0.64) 8 0.26 (0.09-0.77) 9 0.26 (0.07-1.04) 
Meningitec MenACWY-TT 13 0.31 (0.11-0.83) 13 0.32 (0.13-0.82) 6 0.67 (0.05-8.17) 7 0.17 (0.07-0.4) 
NeisVac-C MenACWY-TT 15 0.27 (0.14-0.52) 15 0.26 (0.13-0.51) 6 0.23 (0.04-1.38) 9 0.28 (0.15-0.51) 
Menjugate MenACWY-CRM 16 0.63 (0.31-1.3) 16 18.81 (12.72-27.82) 8 7.27 (3.72-14.21) 8 5 (2.27-11) 
Meningitec MenACWY-CRM 12 0.73 (0.45-1.18) 12 14.07 (6.21-31.88) 5 3.08 (0.65-14.49) 5 2.77 (0.67-11.43) 
NeisVac-C MenACWY-CRM 18 0.75 (0.44-1.27) 17 16.01 (10.16-25.22) 10 5.26 (2.65-10.44) 8 5.05 (1.98-12.9) 
  Proportions ≥0.1 IU/mL 
  Pre-boost 1 month post-boost 6 months post-boost 9 months post-boost 
  n % ≥0.1 IU/mL n % ≥0.1 IU/mL n % ≥0.1 IU/mL n % ≥0.1 IU/mL 
Menjugate All 33 82 33 85 16 88 17 82 
Meningitec All 25 88 25 88 11 91 12 83 
NeisVac-C All 33 85 32 88 16 81 17 88 
all MenACWY-TT 45 73 45 73 20 70 25 72 
all MenACWY-CRM 46 96 45 100 23 100 21 100 
Menjugate MenACWY-TT 17 71 17 71 8 75 9 67 
Meningitec MenACWY-TT 13 77 13 77 6 83 7 71 
NeisVac-C MenACWY-TT 15 73 15 73 6 50 9 78 
Menjugate MenACWY-CRM 16 94 16 100 8 100 8 100 
Meningitec MenACWY-CRM 12 100 12 100 5 100 5 100 
NeisVac-C MenACWY-CRM 18 94 17 100 10 100 8 100 
*p<0.001 vs MenACWY-TT, normal errors regression, adjusting for primary vaccine.  
Supplemental Digital Content (Including Separate Legend)
Click here to download Supplemental Digital Content (Including Separate Legend): SDC 7 - TABLE S5 - REVISION p44.docx 
 45 
 
 
 
0.01
0.1
1
10
100
0 100 200 300 400
Ig
G
 C
o
n
ce
n
tr
at
io
n
 
Days since vaccination 
Men C   
0.01
0.1
1
10
100
1000
0 100 200 300 400
Ig
G
 C
o
n
ce
n
tr
at
io
n
 
Days since vaccination 
Men W  
0.01
0.1
1
10
100
1000
0 100 200 300 400
Ig
G
 C
o
n
ce
n
tr
at
io
n
 
Days since vaccination 
Men A  
0.01
0.1
1
10
100
1000
0 100 200 300 400
Ig
G
 C
o
n
ce
n
tr
at
io
n
 
Days since vaccination 
Men Y  
Supplemental Digital Content (Including Separate Legend)
Click here to download Supplemental Digital Content (Including Separate Legend): SDC 8 - FIGURE S2 - REVISION p45.pdf 
